To investigate the burden of ankylosing spondylitis in the Czech Republic as a baseline for future health economic evaluations. Data were obtained from two cross-sectional studies Beda I (2005) and Beda II (2008), performed in 1,008 and 509 patients, respectively. Methodology used was Cost-of-Illness prevalence-based analysis bottom-up approach. Analysis was performed from payer (health insurance companies) and societal perspective (including productivity costs using friction cost approach). Mean age of sample in Beda I and Beda II was 50.2 and 52.5 years, male were present by 61.0 and 62.7 %; average disease duration was 23.0 and 26.4 years, respectively. Mean total annual costs per patient in the sample were €4,782 in Beda I and €5806 in Beda II. Average direct costs per patient in the sample per year are estimated at €1,812 (Beda I) and €2,588 (Beda II) with the average productivity costs €2,970 (Beda I) and €3,218 (Beda II). We observed a small decrement in percentage (6.7 %) of productivity costs for Beda II as an influence of higher consumption of biologic drugs, hence higher direct costs and possible productivity preservation. The largest direct cost burdens were spa procedures (45.3 %, Beda I) and biological drugs (52.8 %, Beda II). Unique analysis of the burden of the AS in the Central-Eastern Europe presents health care resource and cost consumption by comparing two cross-sectional prevalence-based studies. Further analysis should be carried to obtain data connecting health status with costs consumption in order to analyse the AS from this perspective.

000      

00000naa a2200000 a 4500

001      

bmc14051205

003      

CZ-PrNML

005      

20140411091910.0

007      

ta

008      

140401s2013 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00296-012-2542-x $2 doi

035    __

$a (PubMed)23314983

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Petříková, Alena

245    14

$a The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008 / $c A. Petříková, T. Doležal, J. Klimeš, M. Vocelka, L. Sedová, J. Kolář,

520    9_

$a To investigate the burden of ankylosing spondylitis in the Czech Republic as a baseline for future health economic evaluations. Data were obtained from two cross-sectional studies Beda I (2005) and Beda II (2008), performed in 1,008 and 509 patients, respectively. Methodology used was Cost-of-Illness prevalence-based analysis bottom-up approach. Analysis was performed from payer (health insurance companies) and societal perspective (including productivity costs using friction cost approach). Mean age of sample in Beda I and Beda II was 50.2 and 52.5 years, male were present by 61.0 and 62.7 %; average disease duration was 23.0 and 26.4 years, respectively. Mean total annual costs per patient in the sample were €4,782 in Beda I and €5806 in Beda II. Average direct costs per patient in the sample per year are estimated at €1,812 (Beda I) and €2,588 (Beda II) with the average productivity costs €2,970 (Beda I) and €3,218 (Beda II). We observed a small decrement in percentage (6.7 %) of productivity costs for Beda II as an influence of higher consumption of biologic drugs, hence higher direct costs and possible productivity preservation. The largest direct cost burdens were spa procedures (45.3 %, Beda I) and biological drugs (52.8 %, Beda II). Unique analysis of the burden of the AS in the Central-Eastern Europe presents health care resource and cost consumption by comparing two cross-sectional prevalence-based studies. Further analysis should be carried to obtain data connecting health status with costs consumption in order to analyse the AS from this perspective.

650    _2

$a absentérství $7 D000041

650    _2

$a balneologie $x ekonomika $7 D001452

650    _2

$a průřezové studie $7 D003430

650    _2

$a náklady na léky $7 D016527

650    _2

$a výkonnost $7 D004526

650    _2

$a ženské pohlaví $7 D005260

650    12

$a náklady na zdravotní péči $7 D017048

650    _2

$a zdravotnické zdroje $x ekonomika $x využití $7 D006295

650    _2

$a lidé $7 D006801

650    _2

$a zdravotní pojištění $x ekonomika $7 D007348

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a ekonomické modely $7 D018803

650    _2

$a prevalence $7 D015995

650    _2

$a pracovní neschopnost $x ekonomika $7 D018582

650    _2

$a ankylózující spondylitida $x diagnóza $x ekonomika $x epidemiologie $x terapie $7 D013167

650    _2

$a časové faktory $7 D013997

651    _2

$a Česká republika $x epidemiologie $7 D018153

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Doležal, Tomáš $u -

700    1_

$a Klimeš, Jiří $u -

700    1_

$a Vocelka, Milan $u -

700    1_

$a Sedová, Liliana $u -

700    1_

$a Kolář, Jozef $u -

773    0_

$w MED00004228 $t Rheumatology international $x 1437-160X $g Roč. 33, č. 7 (2013), s. 1813-9

856    41

$u https://pubmed.ncbi.nlm.nih.gov/23314983 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20140401 $b ABA008

991    __

$a 20140411092000 $b ABA008

999    __

$a ok $b bmc $g 1018341 $s 849785

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2013 $b 33 $c 7 $d 1813-9 $i 1437-160X $m Rheumatology international $n Rheumatol Int $x MED00004228

LZP    __

$a Pubmed-20140401